Please assess the completion status of the following clinical trial:

Trial Title: Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or more~* prior diagnosis of diabetes mellitus (DM)~* persistent micro-or macroalbuminuria (urinary albumin excretion\> 30 mg / g creatinine (AUC) in 3 consecutive measurements on different days)~* glycated hemoglobin \<10%~* maximum dose of ACE-I and / or ARBs.~Exclusion Criteria:~* diagnosis of autoimmune diseases, HIV, hepatitis, cancer, inflammatory disease~* pregnant or lactating patients~* glomerular filtration rate (GFR) \<30 ml/min/1, 73m2 (estimated by the MDRD and the Cockcroft-Gault formula)~* presence of kidney disease unrelated to diabetes~* chronic urinary tract infection~* diagnosis of congestive heart failure (CHF) New York Heart Association (NYHA) class III or IV~* recent history (\<6 months) unstable angina, myocardial infarction, stroke, coronary intervention~* history of alcohol and / or drugs~* mental incapacity to understand the informed consent~* intolerance to green tea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Green tea extract (Type: ACTIVE_COMPARATOR): Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
- Placebo (celulose) (Type: PLACEBO_COMPARATOR): Patients will receive four capsules of placebo (celulose) daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).